Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Provided By GlobeNewswire
Last update: Aug 14, 2025
FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
Evaluation of strategic alternatives
Read more at globenewswire.com3.64
-0.18 (-4.71%)
Find more stocks in the Stock Screener
NERV Latest News and Analysis
